Biogen halts development of controversial Alzheimer's drug

Biogen Inc. BIIB, -0.18% said Wednesday that it will halt the development and commercialization of its Alzheimer’s drug Aduhelm, which drew intense scrutiny of its U.S. regulatory approval process due to concerns about whether its benefits outweighed its risks. The drugmaker said it will continue to advance Leqembi, the Alzheimer’s treatment granted full approval last year by the U.S. Food and Drug Administration and will accelerate development of other potential new treatments. The decision to discontinue ...